Last edition
News about Market
Torrent Pharma Approves USD 1.51 Billion Bond Fundraising Plan
Torrent Pharmaceuticals has approved a plan to raise up to USD 1.51 billion through the issuance of secured, rated, listed and redeemable non-convertible debentures (NCDs), according to a regulatory filing.
Market | 06/01/2026 | By Darshana | 250
Samsung Bioepis Launches BYOOVIZ Biosimilar in Europe
Samsung Bioepis has completed the transfer of BYOOVIZ commercial rights from Biogen, making it the company’s fourth biosimilar directly marketed in Europe, with a pre-filled syringe launch planned for Q2 2026.
Market | 03/01/2026 | By News Bureau | 293
Intelligent Bio Solutions Forms New Manufacturing Partnership to Boost Global Production and Margins
Intelligent Bio Solutions has entered into a manufacturing partnership with Syrma Johari Medtech to expand its global production capacity, strengthen supply-chain resilience, and support an anticipated improvement of approximately 20 percentage points in gross margin ahead of its planned entry into the US market.
Market | 01/01/2026 | By News Bureau | 255
Silo Pharma Signs LOI with Allucent for Phase I Development of SPC-15
Silo Pharma has executed a Letter of Intent (LoI) with Allucent to support the phase I clinical development of SPC-15, with planned single-ascending dose and multiple-ascending dose studies representing a key clinical milestone for its intranasal treatment targeting PTSD and anxiety disorders.
Market | 31/12/2025 | By News Bureau | 264
Johnson & Johnson Acquires Halda Therapeutics to Strengthen Oncology Pipeline with RIPTAC Platform
Johnson & Johnson has completed the acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing oral, targeted therapies for solid tumours using its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The transaction was completed for USD 3.05 billion in cash.
Market | 31/12/2025 | By Darshana | 299
XOMA Royalty and Takeda Amend Mezagitamab Agreement in Royalty Sharing Deal
XOMA Royalty and Takeda have completed a royalty sharing transaction amending their mezagitamab (TAK-079) agreement, with Takeda regaining a majority interest while XOMA Royalty gains milestone and royalty payments linked to nine development-stage assets in Takeda’s externalised portfolio.
Market | 31/12/2025 | By News Bureau | 325
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Market | 30/12/2025 | By News Bureau | 211
Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power
Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.
Market | 30/12/2025 | By News Bureau | 357
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Market | 30/12/2025 | By News Bureau | 267
Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.
Market | 30/12/2025 | By News Bureau | 152
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy